WASHINGTON (Reuters) -U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Return on Equity (ROE): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds ...

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.

On July 14, 2025 Fresenius filed two IPR petitions challenging Regeneron’s patents related to aflibercept. Regeneron has not asserted that ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.

Trump specifically asked that those companies offer the MFN price to Medicaid recipients and to promise that they wouldn't ...

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a ...

SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...